Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I TrialVincent Chung, John S. Kovach, Francis Johnson et al.|Clinical Cancer Research|2016Cited by 126
IMPROVED SURVIVAL AMONGST PATIENTS TREATED WITH ADJUVANT TAMOXIFEN AFTER MASTECTOMY FOR EARLY BREAST CANCERMichael Baum, Sidra Ellis, J. A. Dossett et al.|The Lancet|1983Cited by 117
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or ChemotherapyKai He, Ticiana Leal, Alexander I. Spira et al.|Journal of Thoracic Oncology|2023Cited by 38